US FDA investigates third death after treatment with Sarepta’s gene therapy Elevidys

(Reuters) -The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics’ muscular disorder gene therapy Elevidys.

The death occurred on June 7, the agency said.

(Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)